Zinzino AB (PUBL.): Preliminary Sales Report November 2025
Zinzino group revenue increased with a total of 45 %, compared with the previous year. The revenue in November for Zinzino’s sales markets increased by 49 % and amounted to SEK 375.0 (251.8) million. Faun Pharma’s external sales decreased and amounted to SEK 4.3 (10.1) million.
Overall, the Group increased revenues by 45 % to SEK 379.3 (261.9) million compared with the previous year.
Accumulated revenue for January – November 2025 increased by 54 % to SEK 3,007.5 (1,955.1) million.
Revenues were distributed as follows:
Regions, MSEK
25-Nov
24-Nov
Change
YTD 2025
YTD 2024
Change
The Nordics
29.7
29.0
2%
301.0
272.3
11%
Central Europe
133.9
70.4
90%
892.2
518.7
72%
East Europe
51.5
51.6
0%
361.9
366.0
-1%
South & West Europe
58.7
45.3
30%
513.9
346.7
48%
The Baltics
17.3
16.1
7%
115.4
95.6
21%
North America
58.1
25.8
125%
491.0
179.2
174%
Asia-Pacific
23.0
11.1
107%
263.7
64.4
309%
Africa
2.8
2.5
12%
21.1
15.1
40%
Zinzino
375.0
251.8
49%
2960.2
1858.0
59%
Faun Pharma
4.3
10.1
-57%
47.3
97.1
-51%
Zinzino Group
379.3
261.9
45%
3007.5
1955.1
54%
Countries in regions:
The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
Central Europe: Austria, Germany, Switzerland
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
The Baltics: Estonia, Latvia, Lithuania
North America: Canada, USA, Mexico
Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines, South Korea
Africa: South Africa
View as PDF
SOURCE: Zinzino
About Zinzino
Zinzino AB (publ) (ZZ-B.ST) is a global direct-sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier